Fundamental Analysis of Ocuphire Pharma Inc - Growth / Value Index
OCUP - Valuation Highlights
Valuation Analysis
Tsr Value Index - Poor Score of 21.88
Price to Book Ratio of 213.95 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -835.30 | 1.40 | -27.57 % | |
| Price to Book | 209.59 | 0.807 | 7.86 % | 0.894 |
| Price to Sales | 496.54 | 0.704 | -18.91 % | |
| Enterprise Value to EBITDA Multiple | 0.604 | -0.355 | 19.39 % |
OCUP - Profitability Highlights
Profitability Analysis
Excellent QoQ /QoQ FY EPS growth
Strong Return On Capital Employed of 57.61
Company Earning excess return
Piotroski F Score - Stable Value of 4.0
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Tsr Profitability Index - Very Poor Score of 5.00
Very Low Dividend Yield of 0 %
EPS decline for last four quarters
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -25.09 | 57.61 | 48.91 % | -15.43 |
| Return On Asset | -22.71 | 53.29 | 45.96 % | -13.71 |
| Net Profit Margin | -59.44 | 50.26 | 11.96 % | -415.31 |
| Operating Profit Margin | -63.86 | 50.83 | 11.13 % | -450.50 |
| EBITDA Margin | -60.51 | 50.26 | 9.96 % | -450.50 |
Highlights
| Market Cap | 43552.66 K |
| Enterprise Value | -6948.34 K |
| Price/Book TTM | 209.59 |
| Outstanding Share | 25924.20 K |
| Float/ Outstanding Share | 93.90% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | -0.0456 |
| Piotroski F Score | 4.00 |
| Altman Z Score | 8.28 |
| Sloan Ratio | 0.104 |
| Peter Lynch Fair Value | 0 |
OCUP - Growth Highlights
Growth Analysis
STRONG JUMP IN NET SALE : YoY growth
Tremendous increasing trend in total sale last 3 year
Steady increase in Total Assets for last 3 Years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 19011.00 K | 43.56 % | 1.18 % |
| Gross Profit | 19008.00 K | 52.21 % | 1.36 % |
| EBITDA | -11503.00 K | 57.85 % | 60.85 % |
| Net Profit | -11301.00 K | 60.72 % | 48.20 % |
| EPS | -0.0020 | 38.06 % | NA |
OCUP - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 95.00
Altman Z Score of 8.41 suggests good Stability
Company is Debt Free
Net Debt zero balance-sheet with high liquidity
Cash ratio of 12.50
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0 | 0 % | 0 |
| Cash Ratio | 12.50 | -19.39 % | |
| Quick Ratio | 0 | 0 % | 8.96 |
| Shareholders Equity | 92.51 | -1.98 % | |
| Debt to EBITDA | 0 | 0 % |
Historical Valuation Ratios of Ocuphire Pharma Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Ocuphire Pharma Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Ocuphire Pharma Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Ocuphire Pharma Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)